INVESTIGATION OF POST-VACCINATION IMMUNITY AGAINST HEPATITIS B IN MEDICAL PERSONNEL OF TUBERCULOSIS HOSPITAL


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The strength and duration of an immune response to hepatitis B virus (HBV) after vaccination among the medical personnel of a tubercular center and a need for their vaccination were studied. Serum samples from 96 medical workers of the clinic were studied; Engerix vaccine was used in accordance with the standard scheme (0-1-6 months) in the period from 1998 to 2008. The markers of hepatitis B (HBsAg, anti-HBs, anti-HBc) and hepatitis C (anti-HCV) viruses were tested by enzyme immunoassay. All anti-HBsAg positive samples were examined for HCV RNA using PCR. For the analysis of post-infection immunity (protective criterion), the antibody detection rates were as follows: anti-HBs, 10 mIU/ml or more (low titers, 10-199 mIU/ml; medium titers, 200-5000 mIU/ml; high titers, over 5000 mIU/ml). The medical workers were proven to remain a risk group for parenteral hepatic infections: the presence of isolated anti-HBc in 5.2% of cases; the discovery of anti-HCV in 3.1% of the persons with HCV RNA, in the absence of clinical and biochemical parameters, is suggestive of latent HBV and HCV infections. Almost every three (28.1%) medical workers with anti-HBs were found to have anti-HBc, which might suggest prior HBV infection. It was ascertained that 21.9% of the medical workers had no post-vaccination antibodies to HBV in the protective titer in the analyzed period. Among 78.1% of the medical personnel having protective levels of antibodies to HBV (anti-HBs), 54, 20, and 26% had low, medium, and high antibody titers, respectively. A dynamic investigation for postvaccination immunity to HBV showed that the proportion of individuals with the concentration of protective antibody titers among the medical staff was 84.2% one year after completion of vaccination. However, the number of persons with protective titers of antibodies to HBV decreased with years. According to the time of vaccination, there was a reduction in the number of persons with high titers of antibodies to HBV and simultaneously an increase in the number of subjects with low and medium titers of antibodies to HBV. The strength of post-vaccination immunity to HBV among different groups of medical personnel in the tuberculosis center depends on the kind of professional activity.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. ASRATYAN

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health and Social Development of Russia

Email: zasratyan@yahoo.com

D. SOLOVYEV

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health and Social Development of Russia

E. MUSINA

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health and Social Development of Russia

Yu. GARMASH

Moscow City Research-and-Practical Center for Tuberculosis Control

O. RODINA

Moscow City Research-and-Practical Center for Tuberculosis Control

L. ZAROVNAYA

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health and Social Development of Russia

S. KAZARYAN

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health and Social Development of Russia

V. LITVINOV

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Ministry of Health and Social Development of Russia

Әдебиет тізімі

  1. Асратян А.А., Исаева О.В., Михайлов М.И. Тенденция и анализ эпидемической ситуации по парентеральным вирусным гепатитам В и С в Российской Федерации и отдельных регионах. Журн. микробиол. 2005; 4: 40—45.
  2. Онищенко Г.Г. Актуальные вопросы обеспечения санитарного и эпидемиологического благополучия населения Российской Федерации (материалы к докладу). М., 2009.
  3. Шляхтенко Л.И., Сулягина Л.Г. Эпидемиологический контроль хронических вирусных гепатитов В и С как социально значимая проблема: Материалы 6-й Всерос. науч.-практ. конф. «Вирусные гепатиты — проблемы эпидемиологии, диагностики, лечения и профилактики». М., 2005: 395-397.
  4. Асратян А.А. Современная эпидемиологическая характеристика вирусных гепатитов А и В: Автореф. дис.. д-ра мед. наук. М., 1997.
  5. Онищенко Г.Г., Шахгильдян И.В., Михайлов М.И. Оценка эффективности массовой вакцинации против гепатита В в Российской Федерации. Мир вирусных гепатитов 2009; 3: 22-23.
  6. Ohno T., Mizokami M. Genotyping with type-specific primers that саn type HCV types 1-6. Methods in modular medicine. Hepatitis C protocols 1998; 19: 159-164.
  7. Ганина А.А. «Скрытая» ВГВ-инфекция среди доноров крови и лиц, относящихся к группам риска инфицирования: Автореф. канд. мед. наук. М., 2009.
  8. Кюрегян К.К., Попова О.Е., Исаева О.В. и др. Скрытая ВГВ-инфекция в Российской Федерации - результаты популяционного исследования. Мир вирусных гепатитов 2009; 3: 3-6.
  9. Плотникова В.А., Лебедева О.В., Васильева В.А., Мукомолов С.Л. Длительность и напряженность поствакцинального иммунитета у медицинских работников, привитых против гепатита В. Мир вирусных гепатитов 2009; 3: 24-25.
  10. Попова О.Е. Оценка гуморального иммунного ответа на вакцинацию против гепатита В и А: Автореф.. канд. мед. наук. М., 2004.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2012

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>